Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

AstraZeneca selects Cyprotex for drug discovery support

Cyprotex (LSE: CRX) today announces that it has entered into an agreement with AstraZeneca AB (LSE:AZN) to provide drug discovery support.

Under the terms of the agreement, Cyprotex will investigate one of the key properties of potential drugs that determines the dose needed to elicit a therapeutic effect when given to a patient. This laboratory-based assay will be performed on compounds from AstraZeneca's early drug discovery projects and is one of a number of different technologies that Cyprotex uses to help partners evaluate and optimise the drug-like properties of candidate drugs.

Commenting on the agreement with AstraZeneca, David Leahy, CSO of Cyprotex said: "We have established a powerful combination of experimental and computational approaches for the early evaluation of compounds in drug discovery. This deal with AstraZeneca, a leading pharmaceutical company, further validates our developing science and technology platform."

Anders Tunek, Director of DMPK and Bioanalytical Chemistry at AstraZeneca R&D M�lndal, Sweden, said: "Cyprotex has presented a way for us to gain high quality data on our compounds with flexibility to meet our changing needs. We are very impressed by the capabilities that Cyprotex have developed and are looking forward to a close and productive collaboration."


For further information:

Dr David Leahy, CSO
Cyprotex PLC

Tel: +44 (0) 1625 505 100

Dr Anders Tunek
Director of DMPK and Bioanalytical Chemistry
AstraZeneca R&D M�lndal
Tel: +46 705 23 63 34

Media enquiries:

Henry Harrison-Topham/ Heather Salmond
Bankside Consultants Limited

Tel: +44 (0) 20 7444 4141

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.